BR1019 / Boryung Group - LARVOL DELTA

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers (clinicaltrials.gov) - P1 | N=52 | Completed | Sponsor: Boryung Pharmaceutical Co., Ltd | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers (clinicaltrials.gov) - P1 | N=52 | Active, not recruiting | Sponsor: Boryung Pharmaceutical Co., Ltd | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-3" and "BR1019-2" in Healthy Volunteers (clinicaltrials.gov) - P1 | N=52 | Not yet recruiting | Sponsor: Boryung Pharmaceutical Co., Ltd

New P1 trial • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2" (clinicaltrials.gov) - P1 | N=52 | Completed | Sponsor: Boryung Pharmaceutical Co., Ltd | Recruiting ➔ Completed

Trial completion • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2" (clinicaltrials.gov) - P1 | N=52 | Recruiting | Sponsor: Boryung Pharmaceutical Co., Ltd

New P1 trial • Cardiovascular • Diabetes • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus